Dr. Maris is co-leading a study that aims to develop patient-specific cancer vaccines that could be applied to patients in remission to prevent relapse.
A leading physician-researcher at Children’s Hospital of Philadelphia (CHOP) has received an award from the QED Program of the University City Science Center to help develop an innovative T-cell based treatment for the childhood cancer neuroblastoma.
John Maris, MD, distinguished neuroblastoma researcher at CHOP, received the the National Cancer Institute's prestigious Outstanding Investigator Award.